DelveInsight’s, “Frontotemporal Dementia Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in the Frontotemporal Dementia pipeline landscape. It covers the Frontotemporal Dementia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Frontotemporal Dementia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Frontotemporal Dementia Pipeline Report

• DelveInsight’s Frontotemporal Dementia pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Frontotemporal Dementia treatment.
• The leading companies working in the Frontotemporal Dementia Market include Prevail Therapeutics, Coya Therapeutics, Alector Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others.
• Promising Frontotemporal Dementia Pipeline Therapies in the various stages of development include DNL593, Methylprednisolone, Sirolimus, PBFT02, AL001, TRx0237, Galantamine Hydrobromide, and others.
• June 2023: Passage Bio Inc. announced a study of Phase 1 & 2 Clinical Trials for PBFT02. PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with frontotemporal dementia and mutations in the progranulin gene (FTD-GRN).
• August 2023: Denali Therapeutics Inc. announced a study of Phase 1 & 2 Clinical Trials for DNL593. This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period.

 

Request a sample and discover the recent advances in Frontotemporal Dementia Treatment Drugs @ Frontotemporal Dementia Infection Pipeline Report

 

The Frontotemporal Dementia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Frontotemporal Dementia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Frontotemporal Dementia clinical trial landscape.

 

Frontotemporal Dementia Overview

Frontotemporal dementia (FTD) or frontotemporal degeneration refers to a group of disorders caused by progressive nerve cell loss in the brain’s frontal lobes (the areas behind your forehead) or its temporal lobes (the regions behind your ears).

 

Find out more about Frontotemporal Dementia Treatment Drugs @ Drugs for Frontotemporal Dementia Treatment

 

Frontotemporal Dementia Emerging Drugs Profile

• PR 006: Prevail Therapeutics
• Latozinemab: Alector
• PBFT-02: Passage Bio
• WVE-004: WaVe life Sciences
• EXO-050: Coya Therapeutics

 

Frontotemporal Dementia Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Frontotemporal Dementia. The Frontotemporal Dementia companies which have their Frontotemporal Dementia drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

 

Learn more about the emerging Frontotemporal Dementia Pipeline Therapies @ Frontotemporal Dementia Clinical Trials Assessment

 

Scope of the Frontotemporal Dementia Pipeline Report

• Coverage- Global
• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Frontotemporal Dementia Companies- Prevail Therapeutics, Coya Therapeutics, Alector Inc., Passage Bio, WaVe life Sciences, CAMP4 Therapeutics, SOLA Biosciences, Denali Therapeutics, Neurimmune, Autifony Therapeutics, and others.
• Frontotemporal Dementia Pipeline Therapies- DNL593, Methylprednisolone, Sirolimus, PBFT02, AL001, TRx0237, Galantamine Hydrobromide, and others.

 

Dive deep into rich insights for new drugs for Frontotemporal Dementia treatment, Visit @ Frontotemporal Dementia Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Frontotemporal Dementia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Frontotemporal Dementia– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Latozinemab: Alector
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. PR 006 : Prevail Therapeutics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. EXO-050: Coya Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Frontotemporal Dementia Key Companies
21. Frontotemporal Dementia Key Products
22. Frontotemporal Dementia- Unmet Needs
23. Frontotemporal Dementia- Market Drivers and Barriers
24. Frontotemporal Dementia- Future Perspectives and Conclusion
25. Frontotemporal Dementia Analyst Views
26. Frontotemporal Dementia Key Companies
27. Appendix

 

For further information on the Frontotemporal Dementia pipeline therapeutics, reach out to Frontotemporal Dementia Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking